• Editorial
    • Genes & Diseases,Volume 4, Issue 1,2014, Pages 1-3
    • Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)
    Abstract
    We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.
    Keywords
    ANG1005; Brain metastasis; Breast cancer; LRP-1; The blood-brain-barrier
    Copyright © 2014 Chongqing Medical University. Published by Elsevier B.V

    Share

    Recommended Articles
    Fei Li,Shou-Ching Tang.Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)[J].Genes & Diseases,2017;4(1):1-3.